Krishna Institute of Medical Sciences DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.71×	0.73×	0.74×	0.73×	0.75×
	0.54×	0.64×	0.92×	0.93×	1.02×
	11.9%	13.3%	20.0%	19.8%	21.6%
	0.58×	0.58×	0.63×	0.74×	1.14×
	3.03×	3.03×	2.37×	1.84×	1.52×
	8.1%	10.9%	20.4%	18.3%	28.8%
	11.0%	11.0%	19.4%	17.7%	21.8%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

KIMS₹702.50

Krishna Institute of Medical Sciences Ltd.

· Pharma & Health

₹ CrorePeersAPOLLOHOSP MAXHEALTH FORTIS JUBLPHARMA INDGN ONESOURCE PFIZER POLYMEDMcap ₹28,100 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.75	0.73	0.74	0.73	0.71
Interest Burden (Pretax/EBIT) ×	1.02	0.93	0.92	0.64	0.54
EBIT Margin %	21.60	19.77	19.96	13.29	11.92
Asset Turnover ×	1.14	0.74	0.63	0.58	0.58
Financial Leverage (Assets/Equity) ×	1.52	1.84	2.37	3.03	3.03
ROE (5-step product, year-end total equity) %	28.80	18.32	20.42	10.90	8.12
ROE (owners' profit / average owners' equity) %	21.84	17.73	19.39	11.01	11.01

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.